The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker

Journal of Dermatological Science

Volumn 61, Issue 3, 2011, Pages 187-193

  Kanemaru, Hisashi ^a   Fukushima, Satoshi ^a   Yamashita, Junji ^a   Honda, Noritoshi ^a   Oyama, Rie ^a   Kakimoto, Asako ^a   Masuguchi, Shinichi ^a   Ishihara, Tsuyoshi ^a   Inoue, Yuji ^a   Jinnin, Masatoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Melanoma; MicroRNA 221; Serum; Tumor marker

Indexed keywords

MICRORNA; MICRORNA 221; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT MONITORING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA PURIFICATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79951577685     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.12.010     Document Type: Article

References (34)

1. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
2. Mouawad R., Spano J., Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res 2010, 20:67-76.
3. Ikuta Y., Nakatsura T., Kageshita T., Fukushima S., Ito S., Wakamatsu K., et al. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin Cancer Res 2005, 11:8079-8088.
4. Calin G., Croce C. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
5. Esquela-Kerscher A., Slack F. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
6. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
7. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008, 141:672-675.
8. Osaki M., Takeshita F., Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008, 13:658-670.
9. Ciafrè S.A., Galardi S., Mangiola A., Ferracin M., Liu C.G., Sabatino G., et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005, 334:1351-1358.
10. le Sage C., Nagel R., Egan D.A., Schrier M., Mesman E., Mangiola A., et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007, 26:3699-3708.
11. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007, 120:1046-1054.
12. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
13. He H., Jazdzewski K., Li W., Liyanarachchi S., Nagy R., Volinia S., et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005, 102:19075-19080.
14. Chun-Zhi Z., Lei H., An-Ling Z., Yan-Chao F., Xiao Y., Guang-Xiu W., et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010, 10:367.
15. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007, 282:23716-23724.
16. Felicetti F., Errico M.C., Segnalini P., Mattia G., Carè A. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther 2008, 8:1759-1765.
17. Mueller D., Bosserhoff A. Role of miRNAs in the progression of malignant melanoma. Br J Cancer 2009, 101:551-556.
18. Igoucheva O., Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009, 379:790-794.
19. Felicetti F., Errico M.C., Bottero L., Segnalini P., Stoppacciaro A., Biffoni M., et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008, 68:2745-2754.
20. Das S.K., Sokhi U.K., Bhutia S.K., Azab B., Su Z.Z., Sarkar D., et al. Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells. Proc Natl Acad Sci USA 2010, 107:11948-11953.
21. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
22. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
23. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
24. Kuehbacher A., Urbich C., Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008, 29:12-15.
25. Chen Y., Gorski D. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008, 111:1217-1226.
26. Furer V., Greenberg J.D., Attur M., Abramson S.B., Pillinger M.H. The role of microRNA in rheumatoid arthritis and other autoimmune diseases. Clin Immunol 2010, 136:1-15.
27. Davidson-Moncada J., Papavasiliou F., Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 2010, 1183:183-194.
28. Liston A., Linterman M., Lu L. MicroRNA in the adaptive immune system, in sickness and in health. J Clin Immunol 2010, 30:339-346.
29. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005, 353:1793-1801.
30. Marcucci G., Radmacher M.D., Maharry K., Mrózek K., Ruppert A.S., Paschka P., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1919-1928.
31. Bosserhoff A.K., Kaufmann M., Kaluza B., Bartke I., Zirngibl H., Hein R., et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997, 57:3149-3153.
32. Alonso S.R., Ortiz P., Pollán M., Pérez-Gómez B., Sánchez L., Acuña M.J., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004, 164:193-203.
33. Curtin J.A., Bausam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
34. Ashida A., Takata M., Murata H., Kido K., Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009, 124:862-868.